LENZ THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
LENZ THERAPEUTICS, INC. (LENZ) reported Increase Decrease In Operating Lease Liability of -$32.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$5.00K.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$27.00K.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $0.00.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $0.00.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$41.36M.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$5.48M.
- LENZ THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2021 was -$1.76M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$32.00K 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | -$27.00K 10-Q · filed 2026-05-11 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | |||
| 2023-12-31 | -$38.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$39.12M derived: sum of 2 quarters · filed 2024-02-27 | -$40.11M derived: sum of 3 quarters · filed 2024-02-27 | -$41.36M 10-K · filed 2024-02-27 |
| 2023-09-30 | -$376.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.36M derived: sum of 2 quarters · filed 2023-11-13 | -$2.61M 10-Q · filed 2023-11-13 | -$3.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | -$985.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.24M 10-Q · filed 2023-08-14 | -$3.45M derived: sum of 3 quarters · filed 2024-02-27 | -$4.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | -$1.25M 10-Q · filed 2023-05-11 | -$2.47M derived: sum of 2 quarters · filed 2024-02-27 | -$3.65M derived: sum of 3 quarters · filed 2024-02-27 | -$5.64M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$2.39M derived: sum of 2 quarters · filed 2024-02-27 | -$4.38M derived: sum of 3 quarters · filed 2024-02-27 | -$5.48M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$3.17M derived: sum of 2 quarters · filed 2023-11-13 | -$4.27M 10-Q · filed 2023-11-13 | -$6.08M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.09M 10-Q · filed 2023-08-14 | -$4.90M derived: sum of 3 quarters · filed 2023-08-14 | -$4.85M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.10M 10-Q · filed 2023-05-11 | -$2.91M derived: sum of 2 quarters · filed 2023-05-11 | -$2.86M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$1.76M derived: sum of 2 quarters · filed 2023-03-20 | -$1.76M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $57.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |